Dermatology Devices Market Share Grows 12.7% CAGR by 2027-

Dermatology Devices Market

The Dermatology Devices Market is expected to reach USD 11.3 Billion by 2027, from USD 6.2 Billion in 2022, growing at a CAGR of 12.7% during the forecast period. The growth of this market is expected to be driven by the rising incidence of skin disorders, growing awareness of aesthetic procedures, and advancements in technology. However, stringent regulatory policies for medical devices may hamper the growth of this market.

Download the PDF brochure:

Lasers hold the largest share of the dermatology devices market, by type in 2021.

Based on type, the dermatology treatment market is segmented into light therapy devices, lasers, electrosurgical equipment, liposuction devices, microdermabrasion devices, and cryotherapy devices. In 2021, the laser segment accounted for the largest share of the dermatology treatment devices market. The large share of this segment can be attributed to the rising incidence of skin disorders, advancements in technology, and growing preference for minimally invasive procedures.

Hair removal treatment will hold the largest share of the dermatology treatment device market, by application in 2021.

Based on application, the dermatology treatment devices market is segmented into hair removal; skin rejuvenation; acne, psoriasis and tattoo removal; wrinkle removal and skin resurfacing; body remodeling and fat elimination; elimination of vascular and pigmented lesions; warts, skin tags and weight management; and other apps. the hair removal segment accounted for the largest market share of dermatological treatment devices. The large share of this segment can mainly be attributed to the growing number of hair removal procedures.

Request sample pages:

North America accounted for the largest share of the dermatology devices market in 2021.

Based on region, the dermatology devices market is segmented into North America, Europe, Asia Pacific and Rest of the World. In 2021, North America holds the largest market share. The large share of this regional segment can be attributed to factors such as increasing incidence of skin diseases, increased awareness of cosmetic procedures, rapid increase in healthcare expenditures, easy accessibility to advanced technologies and the strong presence of market players in the region.

Major players operating in this dermatology devices market are Alma Lasers, Ltd. (a subsidiary of Sisram Medical Ltd.) (Israel), Cutera, Inc. (USA), Cynosure Inc. (USA), El.En. SpA (Italy), Lumenis, Ltd. (subsidiary of Boston Scientific) (Israel), Solta Medical (subsidiary of Bausch Health Companies Inc.) (USA), Bruker Corporation (USA), Carl Zeiss (Germany), Candela Corporation (USA), Genesis Biosystems, Inc. (USA), HEINE Optotechnik GmbH & Co. KG (Germany), Michelson Diagnostics Ltd. (United Kingdom), PhotoMedex, Inc. (United States), Leica Microsystems (subsidiary of Danaher Corporation) (United States), Olympus Corporation (Japan), FotoFinder Systems GmbH (Germany), Canfield Scientific, Inc. (United States United States), Beijing Toplaser Technology Co., Ltd. (China), DermLite (USA), Syneron Medical Ltd. Apax Partners) (United States), Aerolase (United States) and Bovie (subsidiary of Symmetry Surgical) (United States).

Main developments

In 2022, Cynosure, Inc. collaborated with Clayton, Dubilier & Rice and announced a new $60 million investment from lead investor Clayton, Dubilier & Rice

In 2021, Lumenis entered into a definitive agreement to sell Lumenis’ surgical business to Boston Scientific. The acquisition of Lumenis Surgical (including its strong product portfolio, global team and Israel’s Surgical Laser Center of Excellence) represents a major milestone for the Lumenis team and will enable Boston Scientific to improve the execution of its strategy in urology.

In 2022, Candela collaborated with The Vascular Birthmarks Foundation, Dr. Giacomo Colletti, Laserplast, this collaboration allowed more than 30 pre-qualified patients from 13 countries to receive free laser treatments in Milan

In 2022, Canfield Scientific, Inc. acquired Medici Medical srl to create Canfield Scientific srl, open a state-of-the-art facility near Modena, and launch a medical dermatology training program.

In 2021, Alma launched Alma PrimeX, a non-invasive platform for body contouring and skin tightening.

In 2021, Alma launched Alma Hybrid, which exclusively combines 3 powerful energy sources to deliver effective results.

Talk to the analyst:

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Office 430
Northbrook, Illinois 60062
USA: +1-888-600-6441
Email: [email protected]

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats that will impact 70%-80% of global business revenue. Currently serving 7,500 customers worldwide, including 80% of global Fortune 1000 companies as customers. Nearly 75,000 senior executives from eight industries around the world approach MarketsandMarkets™ for their revenue decision issues.

Our 850 full-time analysts and MarketsandMarkets™ SMEs track global high-growth markets by following the “Growth Engagement Model – GEM”. The GEM aims for proactive collaboration with customers to identify new opportunities, identify most important customers, write “Attack, Avoid and Defend” strategies, identify additional sources of revenue for the company and its competitors. MarketsandMarkets™ now offers 1,500 MicroQuadrants (positioning top performers among Leaders, Emerging Companies, Innovators, Strategic Players) each year in high-growth emerging segments. MarketsandMarkets™ is determined to benefit over 10,000 companies this year for their revenue planning and help them bring their innovations/disruptions to market by providing research ahead of the curve.

MarketsandMarkets’ flagship competitive intelligence and market research platform, “Knowledge Store”, connects over 200,000 markets and entire value chains for a deeper understanding of unmet information, as well as market sizing and niche market forecasts.

This press release was published on openPR.